Global Hepatic Encephalopathy Drug Market Size By Type (RBX-2660, KLS-13019), By Application (Clinic, Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Hepatic Encephalopathy Drug Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.4 billion by 2031, expanding at a CAGR of 7.9% during the forecast period from 2023 to 2031. This growth is primarily fueled by the increasing prevalence of liver disorders such as cirrhosis and hepatitis, rising geriatric population, and heightened awareness around early diagnosis and treatment of hepatic encephalopathy (HE). Advances in therapeutic drug development and strategic initiatives by pharmaceutical companies further accelerate market expansion. Additionally, improved healthcare infrastructure and expanding access to advanced treatments in emerging economies support long-term growth prospects.

Drivers

1. Rising Prevalence of Liver Diseases:

The global burden of liver conditions such as cirrhosis, hepatitis B and C, and non-alcoholic fatty liver disease (NAFLD) is a key driver. These conditions significantly elevate the risk of hepatic encephalopathy, creating strong demand for therapeutic solutions.

2. Growing Geriatric Population:

Older adults are more susceptible to liver dysfunction and its complications. As global aging accelerates, the demand for hepatic encephalopathy drugs is expected to increase accordingly.

3. Advancements in Drug Formulations:

New drug delivery systems, combination therapies, and second-generation formulations—such as rifaximin and lactulose—offer improved efficacy and safety profiles, fostering broader adoption among healthcare professionals.

Restraints

1. High Cost of Treatment:

The cost of long-term hepatic encephalopathy management, especially with branded drugs like rifaximin, can be prohibitive in low- and middle-income regions, restricting patient access.

2. Side Effects and Limited Patient Compliance:

Adverse effects associated with certain drugs, including gastrointestinal discomfort and potential resistance, impact patient compliance, limiting the effectiveness of treatment protocols.

Opportunity

1. Emerging Markets Expansion:

Countries in Asia-Pacific and Latin America are witnessing improvements in healthcare access and insurance coverage. Pharmaceutical companies entering these markets with affordable and effective drug options are likely to see strong growth.

2. Biologic and Personalized Therapies:

Research into microbiome-targeted therapies and personalized treatment approaches presents significant opportunities for innovation in hepatic encephalopathy management.

Market by Drug Type Insights

In 2023, the Lactulose segment held the largest market share, favored for its cost-effectiveness and widespread usage as the first-line treatment. However, the Rifaximin segment is anticipated to grow at the fastest pace during the forecast period, due to its superior efficacy in reducing recurrence of overt hepatic encephalopathy and better tolerability in long-term use.

Market by Route of Administration Insights

Oral drugs dominated the market in 2023 due to patient preference, ease of administration, and high availability of oral formulations. Meanwhile, intravenous (IV) treatments are expected to gain momentum in hospital settings for acute episodes of HE requiring rapid intervention.

Market by Regional Insights

North America led the global market in 2023, supported by advanced healthcare infrastructure, high diagnosis rates, and widespread access to branded drugs like Xifaxan (rifaximin). However, Asia-Pacific is poised to witness the highest growth rate due to rising awareness, increasing disposable income, and the growing incidence of liver diseases.

Competitive Scenario

Key players in the Global Hepatic Encephalopathy Drug Market include Salix Pharmaceuticals (Bausch Health), Lupin Pharmaceuticals, Umecrine Cognition AB, Mallinckrodt Pharmaceuticals, Ferring Pharmaceuticals, Cosmo Pharmaceuticals, and Kora Healthcare. These companies are engaged in strategic collaborations, new drug launches, and geographic expansion to enhance their market presence.

Recent Developments

2023: Salix Pharmaceuticals received FDA clearance for a new rifaximin formulation with improved pharmacokinetics.

2024: Umecrine Cognition AB initiated Phase III trials for a novel GABA-A receptor modulator targeting HE symptoms.

2025: Lupin Pharmaceuticals launched a cost-effective lactulose oral solution for Asian and African markets to strengthen its generic portfolio.

Scope of Work – Global Hepatic Encephalopathy Drug Market

FAQs

1) What is the current market size of the Global Hepatic Encephalopathy Drug Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Hepatic Encephalopathy Drug Market?

The increasing prevalence of liver diseases such as cirrhosis and hepatitis is a major growth driver.

3) Which is the largest region during the forecast period in the Global Hepatic Encephalopathy Drug Market?

North America is the largest regional market, driven by advanced healthcare infrastructure and high awareness levels.

4) Which segment accounted for the largest market share in the Global Hepatic Encephalopathy Drug Market?

The Lactulose drug segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Hepatic Encephalopathy Drug Market?

Key players include Salix Pharmaceuticals, Lupin Pharmaceuticals, Umecrine Cognition AB, Mallinckrodt Pharmaceuticals, and Ferring Pharmaceuticals.